Safety and Efficacy of Rifampin or Isoniazid Among People With <i>Mycobacterium tuberculosis</i> Infection and Living With Human Immunodeficiency Virus or Other Health Conditions: Post Hoc Analysis of 2 Randomized Trials
Jonathon R. Campbell(McGill University Health Centre), Dick Menzies(McGill University Health Centre), Hamdan Al‐Jahdali(King Saud University), Boubacar Bah(Laboratoire National de Santé), Victoria Cook(Royal Prince Alfred Hospital), Anete Trajman(Universidade Federal do Rio de Janeiro), Kevin Schwartzman(McGill University Health Centre), M Belo(Fundação Técnico Educacional Souza Marques), Richard Long
Cited by 27
Related Papers
Role of Transforming Growth Factor–β in Airway Remodeling in Asthma
|American Journal of Respiratory Cell and Molecular Biology|2010|420
Four Months of Rifampin or Nine Months of Isoniazid for Latent Tuberculosis in Adults
|New England Journal of Medicine|2018|392
Criteria and definitions for the radiological and clinical diagnosis of bronchiectasis in adults for use in clinical trials: international consensus recommendations
|The Lancet Respiratory Medicine|2021|297
Histopathology of Middle East respiratory syndrome coronovirus (<scp>MERS</scp>‐CoV) infection – clinicopathological and ultrastructural study
|Histopathology|2017|290
Improper inhaler technique is associated with poor asthma control and frequent emergency department visits
|Allergy Asthma and Clinical Immunology|2013|283